Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics, Inc. filed a current report to note that it issued a press release with information about its results of operations for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes under the Exchange Act.
Coya Therapeutics (NASDAQ:COYA) filed a Form 8-K reporting the results of its June 26, 2025 Annual Meeting of Stockholders.
- Directors re-elected: Howard Berman, Ph.D. (5,821,649 for), Arun Swaminathan, Ph.D. (6,324,520 for), and Ann Lee, Ph.D. (5,779,312 for); broker non-votes totaled 4,096,866 shares.
- Auditor ratified: Weaver & Tidwell, L.L.P. was approved as independent registered public accounting firm for FY 2025 with 10,355,085 votes for (98.9%), 68,851 against, and 340 abstentions.
No additional proposals were presented and the filing discloses no material changes to operations, strategy, or governance.